We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 713% above its sector, the market expects faster growth.
HLB Pharmaceutical Co., Ltd is a South Korean pharmaceutical firm dedicated to the research and development of peptide-based drugs. Its product line encompasses a wide array of pharmaceutical preparations. These include medications for skeletal muscle relaxation, tranquilizing effects, antihistamine action, hypertension management, pain alleviation, anti-itching, astringent properties, anti-inflammatory relief, alimentary system support, metabolic regulation, ophthalmic conditions, local anesthesia, anti-arteriosclerosis, expectoration, fever reduction, analgesia, diabetes control, chemotherapy, peptic ulcer treatment, central nervous system issues, bacterial infections (antibiotics), digestive assistance, antacid needs, dental care, multivitamin supplementation, parasitic skin diseases, dermatological concerns, urogenital organ function, amino acid replacement, cough suppression, mucus thinning, parasitic worm elimination, diarrhea relief, circulatory system disorders, vitamin deficiencies, skin softening, hemorrhoid treatment, and liver ailments. Additionally, the company is actively developing CTT-004, an investigational therapy for ataxia associated with spinocerebellar degeneration, and offers Contract Manufacturing Organization (CMO) services. The enterprise, established in 1998, was formerly recognized as Mediforum Pharmaceutical Incorporation before adopting the name HLB Pharmaceutical Co., Ltd in October 2020. Its headquarters are located in Namyangju-Si, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 047920.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
